We are pleased to announce that PHASTAR is attending Scotland’s Life Sciences Dinner and Annual Awards - an important event in the life sciences calendar.
PHASTAR will be attending the PSI Medical Statistics Taster Day on 28th February at the University of Leicester. It is promising to be an informative event for those who are interested in a career in medical statistics.
PHASTAR will have an exhibition stand at Stamford Court so come and say hello if you’d like to know what a career at PHASTAR could offer you.
From 6pm we will be also be providing food and drinks at the Indian restaurant Shimla Pinks for those who may be interested in working for us.
We attended a seminar hosted by the UK Bioindustry Association at the BIO-Europe conference in Berlin in November 2017. Speakers included a few mainland Europe based industry leaders whose companies had a UK component, as well as Lord O'Shaughnessy, UK health minister for life sciences and BREXIT. At the start of the seminar it was noted how much of the European workload that the UK contributes to: 20% of EMA licensing and 30% of the pharmacovigilance work.
What do we do?
PHASTAR is a quality-focused specialist CRO offering statistical consultancy, clinical trial reporting and data management services by providing expert consultants and delivering in‑house projects.
Who are we?
Founded in 2008 by Kevin Kane, due to our reputation for delivering high quality data analysis and collection, PHASTAR has grown exponentially and remains one of the world’s fastest growing CROs, winning places on the 2015 Sunday Times Virgin Fast Track 100 and the 2017 FT 1000 fastest growing companies in Europe. PHASTAR has grown to serve its international customers and has established offices in the USA, Australia and Kenya in addition to PHASTAR’s 4 locations in the UK.
Why work for us?
There are many reasons you may wish to join our team:
The clinical research industry is currently undergoing a major shift in their approach towards involving patients in clinical trials as studies are becoming more complex, prices soar and the need for personalised medicine increases. The industry has attempted to do this by developing innovative technology, educating patients and promoting more open lines of communication between industry, physicians, and the media. This has resulted in increased participation and quicker access to market from drug development companies. This article aims to briefly explore the current trends surrounding “patient centricity” and how they can affect the success of a clinical trial.
Over the last 20 years there has been a notable evolution from treating patients as subjects whose sole responsibility is to create data, to treating people, and putting those individuals at the heart of each trial. As physicians and clinical managers have come to realise that the patient experience can ultimately affect the outcome study this understanding has led to the emergence of concept of “patient centricity”.